Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYBN Cybin	$7.17 -5.7%	$7.89	$4.81 ▼ $13.88	$169.14M	0.68	315,302 shs	470,725 shs
KLTO Klotho Neurosciences	$0.78 -1.9%	$1.22	$0.11 ▼ $3.91	$36.57M	10.9	1.73 million shs	1.04 million shs
LYEL Lyell Immunopharma	$10.76 -0.6%	$10.30	$7.65 ▼ $32.40	$208.06M	-0.19	72,043 shs	23,106 shs
TIL Instil Bio	$28.25 +4.7%	$27.76	$9.90 ▼ $92.00	$176.89M	2.16	170,842 shs	94,451 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYBN Cybin	-5.66%	-5.53%	-3.89%	+6.70%	+1,843.09%
KLTO Klotho Neurosciences	-1.90%	-17.13%	-42.30%	+246.84%	+77,899,900.00%
LYEL Lyell Immunopharma	-0.65%	-4.95%	+18.24%	+29.64%	-55.17%
TIL Instil Bio	+4.75%	+8.91%	+18.35%	+93.10%	+170.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYBN Cybin	2.0019 of 5 stars	3.6	0.0	0.0	0.0	0.6	0.8	1.3
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	3.2872 of 5 stars	2.8	5.0	0.0	0.0	1.0	4.2	1.3
TIL Instil Bio	3.0931 of 5 stars	3.5	4.0	0.0	0.0	1.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYBN Cybin	3.25	Buy	$85.00	1,085.50% Upside
KLTO Klotho Neurosciences	0.00	N/A	N/A	N/A
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	39.41% Upside
TIL Instil Bio	3.00	Buy	$119.00	321.24% Upside

Current Analyst Ratings Breakdown

Latest KLTO, CYBN, TIL, and LYEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	CYBN Cybin	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A
LYEL Lyell Immunopharma	$60K	3,444.99	N/A	N/A	$15.56 per share	0.69
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYBN Cybin	-$57.88M	-$3.88	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
KLTO Klotho Neurosciences	-$6.15M	-$0.36	N/A	∞	N/A	N/A	-1,779.01%	-275.01%	8/18/2025 (Estimated)
LYEL Lyell Immunopharma	-$342.99M	-$24.29	N/A	N/A	N/A	-552,328.31%	-85.58%	-68.85%	N/A
TIL Instil Bio	-$74.14M	-$11.97	N/A	N/A	N/A	N/A	-51.67%	-32.77%	N/A

Latest KLTO, CYBN, TIL, and LYEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TIL Instil Bio	-$1.72	-$3.24	-$1.52	-$3.24	N/A	N/A
8/12/2025	Q2 2025	LYEL Lyell Immunopharma	-$3.80	-$2.89	+$0.91	-$2.89	$0.00 million	$0.01 million
5/15/2025	Q1 2025	KLTO Klotho Neurosciences	N/A	-$0.08	N/A	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYBN Cybin	N/A	24.24	24.24
KLTO Klotho Neurosciences	N/A	0.29	0.29
LYEL Lyell Immunopharma	N/A	7.49	7.49
TIL Instil Bio	0.58	30.33	30.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYBN Cybin	17.94%
KLTO Klotho Neurosciences	20.07%
LYEL Lyell Immunopharma	66.05%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
CYBN Cybin	15.00%
KLTO Klotho Neurosciences	26.70%
LYEL Lyell Immunopharma	22.30%
TIL Instil Bio	47.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYBN Cybin	50	23.59 million	17.96 million	Not Optionable
KLTO Klotho Neurosciences	N/A	46.05 million	33.76 million	N/A
LYEL Lyell Immunopharma	270	19.21 million	12.01 million	Optionable
TIL Instil Bio	410	6.56 million	3.46 million	No Data

KLTO, CYBN, TIL, and LYEL Headlines

Recent News About These Companies

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13 at 11:10 AM | finanznachrichten.de

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13 at 6:00 AM | globenewswire.com

Instil Bio Reports Promising Phase 2 Study Results

August 11, 2025 | theglobeandmail.com

Instil Bio stock rises after positive data for cancer therapy in China

July 31, 2025 | za.investing.com

Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test

July 31, 2025 | fiercebiotech.comF

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

July 31, 2025 | globenewswire.com

US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours

July 4, 2025 | pharmabiz.comP

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...

July 3, 2025 | manilatimes.netM

Instil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - Nasdaq

July 3, 2025 | nasdaq.com

Instil Bio stock jumps after FDA clearance of IND application

July 2, 2025 | in.investing.com

Instil Bio Shares Climb After FDA Clears Tumor Treatment Application

July 2, 2025 | marketwatch.com

Instil Bio Shares Surge on FDA Clearance for Investigational Cancer Therapy

July 2, 2025 | msn.com

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 2, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/07/02/3109003/0/en/instil-bio-announces-u-s-f-d-a-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsed-refractory-solid-.html$

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

June 20, 2025 | zacks.com

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

June 16, 2025 | zacks.com

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025 | globenewswire.com

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

June 4, 2025 | zacks.com

Instil Bio appoints new Chief Medical Officer

June 4, 2025 | uk.investing.com

Instil Bio appoints Jamie Freedman as Chief Medical Officer

June 2, 2025 | msn.com

Instil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy Development

June 2, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KLTO, CYBN, TIL, and LYEL Company Descriptions

Cybin NYSE:CYBN

$7.17 -0.43 (-5.66%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$7.34 +0.18 (+2.44%)

As of 04:34 AM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Klotho Neurosciences NASDAQ:KLTO

$0.78 -0.02 (-1.90%)

As of 08/14/2025 04:00 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Lyell Immunopharma NASDAQ:LYEL

$10.76 -0.07 (-0.65%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$10.70 -0.06 (-0.56%)

As of 08/14/2025 04:04 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Instil Bio NASDAQ:TIL

$28.25 +1.28 (+4.75%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$29.06 +0.81 (+2.87%)

As of 05:58 AM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time